Cue Biopharma financials
$25.51−7.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.9M | $5.7M | $21.9M | $2.1M | $3.0M | $421.0K | $1.6M | $3.3M | $2.7M | $1.7M | $1.8M | $2.1M |
| Gross profit | $7.9M | $5.7M | $21.9M | $2.1M | $3.0M | $421.0K | $1.6M | $3.3M | $2.7M | $1.7M | $1.8M | $2.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$87.7M | -$5.4M | $2.0M | -$7.5M | -$8.6M | -$12.3M | -$9.6M | -$8.9M | -$10.4M | -$12.7M | -$13.7M | -$11.4M |
| Net income | -$153.1M | -$5.2M | $1.6M | -$7.4M | -$8.5M | -$12.3M | -$9.5M | -$8.7M | -$10.2M | -$12.3M | -$13.4M | -$11.0M |
| Net margin | −1943.2% | −91.1% | 7.2% | −346.6% | −287.1% | −2911.4% | −602.5% | −259.6% | −382.7% | −719.1% | −737.7% | −524.0% |
| Diluted EPS | $-24.14 | $-1.08 | $0.17 | $-2.10 | $-2.67 | $-4.95 | $-3.83 | $-5.10 | $-6.00 | $-7.50 | $-8.54 | $-7.20 |
| EBITDA | -$87.7M | -$4.8M | $2.6M | -$7.5M | -$8.5M | -$12.2M | -$9.5M | -$8.8M | -$10.3M | -$12.6M | -$13.6M | -$11.3M |
| Operating cash flow | -$29.0M | -$10.9M | -$1.1M | -$9.0M | -$3.4M | -$8.2M | -$9.0M | -$7.5M | -$10.0M | -$9.8M | -$11.0M | -$7.8M |
| Free cash flow | -$29.0M | -$11.1M | -$1.1M | -$9.0M | -$3.4M | -$8.3M | -$9.0M | -$7.5M | -$10.0M | -$9.8M | -$11.0M | -$7.8M |
| Diluted shares | 6.3M | 4.8M | 9.1M | 3.4M | 3.2M | 2.5M | 2.5M | 1.7M | 1.7M | 1.6M | 1.6M | 1.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.4M | $16.4M | $27.1M | $11.7M | $27.5M | $13.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $7.0M | $0.00 | $0.00 |
| Total debt | $960.0K | $1.0M | $689.0K | $1.6M | $2.6M | $3.9M |
| Total assets | $30.7M | $30.9M | $42.2M | $31.6M | $40.7M | $22.3M |
| Total liabilities | $28.4M | $9.3M | $15.8M | $18.4M | $22.5M | $15.7M |
| Shareholders' equity | $2.3M | $21.6M | $26.4M | $13.2M | $18.2M | $6.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology